albumin binding raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-07. Anything still debated is marked as such rather than presented as settled.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
An airport road was paved over the Jewish cemetery in Damascus, and Jewish schools were closed and handed over to Muslims. The Jewish Quarter of Damascus was under constant surveillance by the secret police, who were present at synagogue services, weddings, bar mitzvahs, and other Jewish gatherings. The secret police closely monitored contact between Syrian Jews and foreigners and kept a file on every member of the Jewish community. Jews also had their phones tapped and their mail read by the secret police. After Israel's victory in the 1967 Six-Day War, restrictions were further tightened, and 57 Jews in Qamishli may have been killed in a pogrom. The communities of Damascus, Aleppo, and Qamishli were under house arrest for eight months following the war. Many Jewish workers were laid off following the Six-Day War. After purging rival Baathist factions through a coup in 1970, Hafez al-Assad established total dominance over the Ba'ath party and established a dictatorship centered around his personality cult. Structure of Assad's police state revolved around the Ba'ath party organization, Syrian military establishment packed with Ba'athist elites and Assad family's Alawite loyalists. Hafez ruled Syria for three decades, deploying repressive measures ranging from censorship to violent methods of state terror such as mass murders, deportations and practices such as torture, which were unleashed collectively upon the civilian population.
Pseudomonas aeruginosa produces the pigments pyocyanin and pyoverdin, which give the colonies a greenish sheen. Some specimens of Serratia marcescens produce an orange-red pigment called prodigiosin. Organisms with swarming motility, like Proteus species, exhibit concentric waves of growth extending from the inoculation point.
R-30490 (also known as 4-methoxymethylfentanyl) is an opioid analgesic related to the highly potent animal tranquilizer carfentanil, and with only slightly lower potency. It was first synthesised by a team of chemists at Janssen Pharmaceutica led by Paul Janssen, who were investigating the structure-activity relationships of the fentanyl family of drugs. R-30490 was found to be the most selective agonist for the μ-opioid receptor out of all the fentanyl analogues tested, but it has never been introduced for medical use in humans, although the closely related drug sufentanil is widely used for analgesia and anesthesia during major surgery. Side effects of fentanyl analogs are similar to those of fentanyl itself, which include itching, nausea and potentially serious respiratory depression, which can be life-threatening. Fentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear.
Morphine, the archetypal opioid, and other opioids (e.g., codeine, oxycodone, hydrocodone, dihydromorphine, pethidine) all exert a similar influence on the cerebral opioid receptor system. Buprenorphine is a partial agonist of the μ-opioid receptor, and tramadol is a serotonin–norepinephrine reuptake inhibitor (SNRI) with weak μ-opioid receptor agonist properties. Tramadol is structurally closer to venlafaxine than to codeine and delivers analgesia by not only delivering "opioid-like" effects (through mild agonism of the μ-opioid receptor) but also by acting as a weak but fast-acting serotonin releasing agent and norepinephrine reuptake inhibitor. Tapentadol, with some structural similarities to tramadol, presents what is believed to be a novel drug working through two (and possibly three) different modes of action in the fashion of both a traditional opioid and as an SNRI. The effects of serotonin and norepinephrine on pain, while not completely understood, have had causal links established and drugs in the SNRI class are commonly used in conjunction with opioids (especially tapentadol and tramadol) with greater success in pain relief. Dosing of all opioids may be limited by opioid toxicity (e.g., confusion, respiratory depression, myoclonic jerks, and pinpoint pupils), seizures (particularly from tramadol), but opioid-tolerant individuals usually have higher dose ceilings than patients without tolerance. Opioids, while very effective analgesics, may have some unpleasant side-effects.
=== Africa === Fake antimalarial medication has been threatening efforts to control malaria in Africa, including the development of antimalarial resistance. Other medicines have been documented to be of dangerously poor quality. In October 2022, the deaths of at least 70 children in Gambia were linked to cough syrups manufactured in India, which had high levels of diethylene glycol and ethylene glycol. There were delays in government response, despite doctors pressing for this. In 2011, according to the World Health Organization (WHO), 64% of Nigeria's imported antimalarial medication drugs were fake. By 2023, the problem of substandard and falsified medicines had lessened somewhat since the peak. Nigeria is Africa's largest drugs market, and over 70% of its drugs are imported from India and China, considered the "biggest source of fakes." One response has been attempts to bolster domestic production of medicines, but challenges include insecurity and unstable electricity. There have been investments in technologies to increase detection and verification of poor-quality medicines. In 2018, Tramadol, a powerful and addictive opioid, became a major problem. A huge black market has emerged, and an increasing number of addicts overdose and die.
Sources: en.wikipedia.org
==== Metal Recycling and e-waste ==== Occupational exposure to PBDEs from e-waste and battery recycling has been found to be a common risk for workers. In southern China, workers have been observed to have high blood PBDE concentrations. E-waste surface dust can also be inhaled as fumes, or dermal contact. Dust particles can become suspended in air, contributing to air pollution, or leach into water and soils. Uncontrolled e-waste handling also poses a hazard to public health, another study has shown that vegetables near e-waste sites have been found to be contaminated with PBDEs.
In biology, sulfation is typically effected by sulfotransferases, which catalyze the transfer of the equivalent of sulfur trioxide to substrate alcohols and phenols, converting the latter to sulfate esters. The source of the SO3 group is usually 3'-phosphoadenosine-5'-phosphosulfate (PAPS). When the substrate is an amine, the result is a sulfamate. Sulfation is one of the principal routes for post-translational modification of proteins. Sulfation is involved in a variety of biological processes, including detoxification, hormone regulation, molecular recognition, cell signaling, and viral entry into cells. It is among the reactions in phase II drug metabolism, frequently effective in rendering a xenobiotic less active from a pharmacological and toxicological standpoint, but sometimes playing a role in the activation of xenobiotics (e.g. aromatic amines, methyl-substituted polycyclic aromatic hydrocarbons). Sulfate is part of sulfolipids, such as sulfatides, which constitute 20% of the galactolipids in myelin. Another example of biological sulfation is in the synthesis of sulfonated glycosaminoglycans, such as heparin, heparan sulfate, chondroitin sulfate, and dermatan sulfate. Sulfation is also a possible posttranslational modification of proteins.
In MODY2, oral agents are relatively ineffective, however most patients are managed conservatively through diet and exercise. In MODY1 and MODY3, sulfonylureas are usually very effective, delaying the need for insulin treatment. Sulfonylureas are effective in the KATP channel forms of neonatal-onset diabetes. The mouse model of MODY diabetes suggested that the reduced clearance of sulfonylureas stands behind their therapeutic success in human MODY patients, but Urbanova et al. found that human MODY patients respond differently to the mouse model and that there was no consistent decrease in the clearance of sulfonylureas in randomly selected HNF1A-MODY and HNF4A-MODY patients. Chronic hyperglycemia due to any cause can eventually cause blood vessel damage and the microvascular complications of diabetes. The principal treatment goals for people with MODY — keeping the blood sugars as close to normal as possible ("good glycemic control"), while minimizing other vascular risk factors — are the same for all known forms of diabetes. The tools for management are similar for all forms of diabetes: blood testing, changes in diet, physical exercise, oral hypoglycemic agents, and insulin injections. In many cases these goals can be achieved more easily with MODY than with ordinary types 1 and 2 diabetes. Some people with MODY may require insulin injections to achieve the same glycemic control that another person may attain with careful eating or an oral medication. When oral hypoglycemic agents are used in MODY, the sulfonylureas remain the oral medication of first resort.
=== Business === Protein Capture Science is a biotech start-up company commercializing a self-removing affinity tag technology for research and large-scale purifications of proteins. Wood and Izabela Gierach are co-founders of the company, based in Columbus, Ohio. The first line of the iCapTag products for protein purification was showcased in the Industry Innovators 2021-2022 Issue of the journal BioProcess International. Protein Capture Science was recently awarded several grants and funding, including highly competitive The Ohio Third Frontier Technology Validation and Start-Up Fund and the Concept Fund for extraordinary technologies by the Department of Development, State of Ohio.
Glycomics is the comprehensive study of glycomes (the entire complement of sugars, whether free or present in more complex molecules of an organism), including genetic, physiologic, pathologic, and other aspects. Glycomics "is the systematic study of all glycan structures of a given cell type or organism" and is a subset of glycobiology. The term glycomics is derived from the chemical prefix for sweetness or a sugar, "glyco-", and was formed to follow the omics naming convention established by genomics (which deals with genes) and proteomics (which deals with proteins).
Sources: en.wikipedia.org
EDTA forms such strong complexes with most divalent cations that it finds many uses. For example, it is often present in washing powder to act as a water softener by sequestering calcium and magnesium ions. The selectivity of macrocyclic ligands can be used as a basis for the construction of an ion selective electrode. For example, potassium selective electrodes are available that make use of the naturally occurring macrocyclic antibiotic valinomycin.
=== Co-release === Neuropeptides are often co-released with other neurotransmitters and neuropeptides to modulate synaptic activity. Synaptic vesicles and dense core vesicles can have differential activation properties for release, resulting in context-dependent co-release combinations. For example, insect motor neurons are glutamatergic and some contain dense core vesicles with proctolin. At low frequency activation, only glutamate is released, yielding fast and rapid excitation of the muscle. At high frequency activation however, dense core vesicles release proctolin, inducing prolonged contractions. Thus, neuropeptide release can be fine-tuned to modulate synaptic activity in certain contexts. Some regions of the nervous system are specialized to release distinctive sets of peptides. For example, the hypothalamus and the pituitary gland release peptides (e.g. TRH, GnRH, CRH, SST) that act as hormones In one subpopulation of the arcuate nucleus of the hypothalamus, three anorectic peptides are co-expressed: α-melanocyte-stimulating hormone (α-MSH), galanin-like peptide, and cocaine-and-amphetamine-regulated transcript (CART), and in another subpopulation two orexigenic peptides are co-expressed, neuropeptide Y and agouti-related peptide (AGRP). These peptides are all released in different combinations to signal hunger and satiation cues. The following is a list of neuroactive peptides co-released with other neurotransmitters. Transmitter names are shown in bold. Norepinephrine (noradrenaline).
Clomipramine is an extremely strong SRI by all accounts. Its affinity for the SERT was reported in one study using human tissues to be 0.14 nM, which is considerably higher than that of other TCAs. For example, the TCAs with the next highest affinities for the SERT in the study were imipramine, amitriptyline, and dosulepin (dothiepin), with Ki values of 1.4 nM, 4.3 nM, and 8.3 nM, respectively. In addition, clomipramine has a terminal half-life that is around twice as long as that of amitriptyline and imipramine. In spite of these differences however, clomipramine is used clinically at the same usual dosages as other serotonergic TCAs (100–200 mg/day). Some health authorities recommend daily dosage is in the range of 30 to 75 mg in single or divided doses. Initial dosage should be 10 mg/day with gradual increments to 30–150 mg/day in divided doses or as a single dose at bedtime. Health Canada recommends maximum dose for outpatients is preferred at 200 mg/day. Sustained-release 75 mg formulation may be preferable at doses above 150 mg/day (i.e. 200 mg to 250 mg/day). It achieves typical circulating concentrations that are similar in range to those of other TCAs but with an upper limit that is around twice that of amitriptyline and imipramine. For these reasons, clomipramine is the most potent SRI among the TCAs and is far stronger as an SRI than other TCAs at typical clinical dosages. In addition, clomipramine is more potent as an SRI than any selective serotonin reuptake inhibitors (SSRIs); it is more potent than paroxetine, which is the strongest SSRI.
Cyclophosphamide (Cytoxan, Procytox), Doxorubicin (Adriamycin) and Vincristine (Oncovin) Paclitaxel (Taxol) Irinotecan (Camptosar) Guidelines recommended as of 2018 that patients who relapse > 6 months from initial therapy should be retreated with the original chemotherapy regimen. For patients who relapse in < 6 months, single-agent chemotherapy either topotecan second-line therapy, or paclitaxel can be used.
Take white (Yemeni) alum, dissolve it and purify it by filtration. Then distil (green?) vitriol with copper-green (the acetate), and mix (the distillate) with the filtered solution of the purified alum, afterwards let it solidify (or crystallise) in the glass beaker. You will get the best qalqadis (white alum) that may be had. In an anonymous Latin work variously attributed to Aristotle (under the title Liber Aristotilis, 'Book of Aristotle'), to al-Razi (under the title Lumen luminum magnum, 'Great Light of Lights'), or to Ibn Sina, the author speaks of an 'oil' (oleum) obtained through the distillation of iron(II) sulfate (green vitriol), which was likely 'oil of vitriol' or sulfuric acid. The work refers multiple times to Jabir ibn Hayyan's Seventy Books (Liber de septuaginta), one of the few Arabic Jabir works that were translated into Latin. The author of the version attributed to al-Razi also refers to the Liber de septuaginta as his own work, showing that he erroneously believed the Liber de septuaginta to be a work by al-Razi. There are several indications that the anonymous work was an original composition in Latin, although according to one manuscript it was translated by a certain Raymond of Marseilles, meaning that it may also have been a translation from the Arabic. According to Ahmad Y. al-Hassan, three recipes for sulfuric acid occur in an anonymous Garshuni manuscript containing a compilation taken from several authors and dating from before c. 1100 AD. One of them runs as follows:
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
The peptide backbone and its fatty acid side chain are susceptible to degradation at elevated temperatures. Refrigeration slows hydrolysis, oxidation, and aggregation processes. Labeled storage ranges reflect stability data generated under defined conditions.